trending Market Intelligence /marketintelligence/en/news-insights/trending/HpmPEUfCe0LjnaD8cfvGdg2 content esgSubNav
In This List

Jazz Pharmaceuticals receives US FDA priority review for leukemia drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Jazz Pharmaceuticals receives US FDA priority review for leukemia drug

The U.S. Food and Drug Administration granted priority review status to the new drug application for Jazz Pharmaceuticals plc's Vyxeos liposome injection, an investigational drug for acute myeloid leukemia, a rapidly progressing and life-threatening blood cancer.

Jazz Pharmaceuticals' application contains clinical data from five studies, including a phase 3 trial which met its primary endpoint.

The drug was previously granted breakthrough therapy designation by the FDA in May 2016 to treat adult patients with therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. It also received fast track designation from the FDA to treat elderly patients with secondary acute myeloid leukemia.

Vyxeos has also received orphan drug designation from the FDA and European Commission for the treatment of acute myeloid leukemia.